Dexmed

# Dexmed ## Overview - **Classification**: Alpha-2 adrenergic agonist. - **Mechanism**: Selectively activates central alpha-2 adrenoceptors, inhibiting norepinephrine release. This leads to sedation, anxiolysis, and analgesia without significant respiratory depression. ## Primary Indications 1. **ICU Sedation**: For intubated and mechanically ventilated adult and pediatric patients. 2. **Procedural Sedation**: For non-intubated adult and pediatric patients before and/or during surgical or other procedures. 3. **Sedation in Non-ICU settings**: Limited to certain procedural sedation and short-term agitation. ## Adult Dosing ### Standard Dosing **ICU Sedation (Intubated/Mechanically Ventilated)** - **Loading Dose**: Optional, **1 mcg/kg** over **10 minutes**. - **Maintenance Dose**: **0.2 to 1 mcg/kg/hour**. - **Frequency**: Continuous infusion. - **Route**: Intravenous infusion. - **Duration**: Up to 24 hours for approved indication; extended use common off-label. **Procedural Sedation (Non-intubated)** - **Loading Dose**: **1 mcg/kg** over **10 minutes**. - **Maintenance Dose**: **0.2 to 1 mcg/kg/hour**. - **Frequency**: Continuous infusion. - **Route**: Intravenous infusion. ### Dose Adjustments - **Renal Impairment**: No routine dose adjustment needed. Limited data. - **Hepatic Impairment**: Dose reduction usually required due to decreased clearance. Consider **50% reduction** or lower starting dose. - **Elderly Patients**: May be more sensitive to hypotensive/bradycardic effects. Start with lower doses and titrate slowly. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Limited data. Often **0.2-0.4 mcg/kg/hour**. - **Frequency**: Continuous infusion. - **Maximum**: Usually kept <**1 mcg/kg/hour**. - **Special Notes**: Higher risk of bradycardia and hypotension; careful titration and monitoring. ### Infants (1-12 months) - **Dose**: **0.2-1.5 mcg/kg/hour**. - **Frequency**: Continuous infusion. - **Maximum**: **1.5 mcg/kg/hour** (higher for short-term, e.g., procedural). ### Children (1-12 years) - **Dose**: **0.2-1.5 mcg/kg/hour**. - **Frequency**: Continuous infusion. - **Maximum**: **1.5 mcg/kg/hour** (up to **2 mcg/kg/hour** reported for agitation). ### Adolescents (13-18 years) - **Dose**: Similar to adult dosing: **0.2 to 1 mcg/kg/hour**. - **Maximum**: **1 mcg/kg/hour** (for continuous infusion). ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to dexmedetomidine or any component. - **Relative**: Advanced heart block (unless paced), severe ventricular dysfunction, acute ischemic stroke. ### Common Adverse Effects - **Very Common (>10%)**: Bradycardia, hypotension, nausea, dry mouth. - **Common (1-10%)**: Hypertension (especially with rapid bolus), atrial fibrillation. - **Serious but Rare**: Asystole, severe bradycardia leading to cardiac arrest, overdose with respiratory depression. ### Key Drug Interactions - **Anesthetics/Sedatives/Hypnotics (e.g., Propofol, Midazolam)**: Potentiation of sedative and hypotensive effects. Consider dose reduction of co-administered agents. - **Opioids**: Additive sedative and respiratory depressant effects. - **Vasodilators (e.g., Nitrates)**: Increased risk of hypotension. - **Beta-blockers/Calcium Channel Blockers**: Increased risk of bradycardia and AV block. ## Monitoring & Follow-up - **Before Treatment**: Baseline vital signs (HR, BP, RR), ECG, consciousness level (e.g., RASS). - **During Treatment**: Continuous cardiac monitoring (HR, BP, ECG rhythm). Respiratory rate and sedation level frequently (e.g., RASS scale). - **Clinical Signs**: Watch for excessive bradycardia, hypotension, over-sedation, or paradoxical agitation. ## Clinical Pearls - 💡 **Tip 1**: Administer loading dose over **10 minutes** to minimize transient hypertension and profound bradycardia. - 💡 **Tip 2**: Patients receiving dexmedetomidine are often easily arousable with verbal or tactile stimulation (cooperative sedation). - 💡 **Tip 3**: Can reduce opioid requirements and help preserve respiratory drive compared to other sedatives. - 💡 **Tip 4**: Not recommended for rapid sequence intubation due to slow onset of deep sedation. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.